Article Text

Download PDFPDF
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

Statistics from


  • Contributors ChP, DP-S, EM-M and AB have written this article. DP-S, PA, MTL-C and ChP have carried out the data collection and databases. AV, DP, MGB, PA, AB and ChP have done the clinical evaluation of patients. JD and ChP have done the statistical analysis. DP-S and FA have performed the laboratory assays.

  • Funding This study was supported by unrestricted grants from Pfizer, and the RETICS Program, RD08/0075 (RIER) from ‘Instituto de Salud Carlos III’ (ISCIII).

  • Competing interests AB has received fees from Roche, Schering-Plough, Wyeth, Abbott, BMS and USB. E.M-M. is a consultant and a member of the Pfizer speakers’ bureaus, MSD, UCB and Abbott. ChP, DP-S, MGB and DP have received speaker honoraria from Pfizer. All other authors have declared no conflicts of interest.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.